Angel Ivanov
About Angel Ivanov
Angel Ivanov is the Executive Director of Immuno-Oncology Solid Tumors, Business Insights and Analytics at Bristol-Myers Squibb in New Jersey, United States. He has over 15 years of experience at Bristol-Myers Squibb, holding various leadership roles in market research across multiple therapeutic areas.
Current Position
Angel Ivanov currently serves as the Executive Director of Immuno-Oncology Solid Tumors, Business Insights and Analytics at Bristol-Myers Squibb. He is based in New Jersey, United States, where he leverages his extensive experience in market research and business analytics to drive insights in the immuno-oncology space.
Previous Roles at Bristol-Myers Squibb
Angel Ivanov has held numerous leadership positions at Bristol-Myers Squibb over the past 15 years. His roles have included Executive Director, Cardiovascular Market Research (2014-2016), Immunoscience Market Research Lead (2013-2014), Virology Market Research Lead (2010-2013), Director of Neuroscience Market Research (2008-2010), and Associate Director of Abilify Market Research (2005-2008). Across these roles, he has developed a strong expertise in market research across multiple therapeutic areas.
Experience at ZS Associates
Prior to joining Bristol-Myers Squibb, Angel Ivanov worked at ZS Associates in Evanston, Illinois. From 2000 to 2005, he held various positions including Associate, Consultant, and Manager. His work there laid a solid foundation for his subsequent roles in the pharmaceutical industry by honing his skills in business insights and analytics.
Educational Background
Angel Ivanov received his Master’s degree from The University of Georgia, completing his studies from 1999 to 2000. His educational background has contributed significantly to his proficiency in business insights and analytics, preparing him for his extensive career in market research within the pharmaceutical industry.
Market Research Expertise
Throughout his career, Angel Ivanov has developed a robust expertise in market research. His extensive experience spans various therapeutic areas including cardiovascular, immunoscience, virology, and neuroscience. His ability to transition between these fields showcases his versatility and deep understanding of the pharmaceutical market.